Wake Forest Baptist scientists win grant to develop more effective treatments for brain cancer

NewsGuard 100/100 Score

Glioblastoma is the most aggressive cancer that originates in the brain. Current therapies can slow the disease, but more often than not can't cure it.

However, thanks to a $9.2 million grant from the National Cancer Institute, scientists at Wake Forest Baptist Medical Center will continue working to develop new, more effective treatments and delivery systems to attack this difficult to manage form of cancer.

"One of the major obstacles to glioblastoma treatment is the accessibility of the tumors to drugs because of the blood-brain and blood-brain tumor barriers," said the principal investigator of the study, Waldemar Debinski, M.D., Ph.D., professor of cancer biology, radiation oncology and microbiology and immunology at Wake Forest Baptist.

"In addition, a surgical approach is often hampered by the inability to fully visualize tumor cells that have migrated away from the tumor and remove them surgically without potentially damaging vital areas of the brain."

Debinski, director of the Brain Tumor Center of Excellence at Wake Forest Baptist, pioneered a method to destroy malignant brain tumor cells without harming healthy cells.

The goal of the five-year grant is to use clinically relevant models to develop the next generation of molecularly targeted drugs to directly attack the tumor mass and cancer cells in surrounding areas where they may have infiltrated. The team also is designing new drug delivery systems to increase access to the tumors by directly accessing the tumor and its vicinities or by disrupting the blood-brain and blood-brain tumor barriers to enhance the therapeutic efficacy of novel drugs, Debenski said.

Source: http://www.wakehealth.edu/

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New AI tool 'TORCH' successfully identifies cancer origins in unknown primary cases